Download MendeleyOrally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of beta-Arrestin in Treatment-Related Dyskinesia in Parkinson's Disease.
Rodriguez Sarmiento, R.M., Berchtold, S., Manevski, N., Lindemann, L., Dey, F., Clairfeuille, T., Amendola, D., Vautrelle, N., Duveau, V., O Connor, E.C.(2025) J Med Chem 68: 13532-13561
- PubMed: 40552668
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00294
- Primary Citation of Related Structures:
9I52, 9I54 - PubMed Abstract:
Dopamine replacement therapies for Parkinson's disease often produce dyskinesias with long-term use. Published studies suggest that introducing β-arrestin signaling might be protective for dyskinesia. We advanced known noncatecholamine D1/D5 receptor G protein-biased agonists and found that removal of oxygen in the linker from published compounds limited β-arrestin recruitment, whereas introduction of nitrogen on the central o -phenyl linker favored β-arrestin recruitment and provided orally bioavailable compounds. Cryogenic electron microscopy suggested key receptor-ligand interactions influencing the different bias behaviors. We discovered compound 24 , a D1/D5 receptor agonist with β-arrestin recruitment and properties for use in vivo . We compared 24 with tavapadon, which shows weak efficacy for β-arrestin signaling, in a rat model of Parkinson's disease with L-DOPA-induced dyskinesias. At particular doses, compound 24 produced efficacy comparable to L-DOPA, but with fewer concomitant dyskinesias. This first in vivo study suggests that β-arrestin may have a positive influence on reducing dyskinesias following acute administration.
- Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel 4070, Switzerland.
Organizational Affiliation:
